Oppenheimer Reiterates Outperform on Tyra Biosciences, Lowers Price Target to $40
Oppenheimer analyst Mazahir Alimohamed reiterates Tyra Biosciences (NASDAQ:TYRA) with a Outperform and lowers the price target from $50 to $40.
Filings · News reference
Tyra Biosciences Files Prospectus To Sell Mixed Securities Shelf Of Undisclosed Amount
Common StockPreferred StockDebt SecuritiesWarrantsUnitsWe may offer and sell the securities identified above from time to time in one or more offerings. This prospectus provides you with a general description of the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Maintains Buy on Tyra Biosciences, Lowers Price Target to $29
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Tyra Biosciences (NASDAQ:TYRA) with a Buy and lowers the price target from $30 to $29.
Stock Market Today: S&P 500, Dow and Nasdaq Futures Fall as Brent Hovers Near $107 and FOMC Commences Two-Day Meeting— MSTR, CRWD, BMM in Focus (UPDATED)
U.S. stock futures declined on Tuesday, as the Dow Jones, S&P 500 and Nasdaq 100 indices fell, following Monday's lower close.
8-K filing — Tyra Biosciences, Inc. (TYRA)
Filed: 2026-09-15 AccNo: 0001193125-26-390951 Size: 561 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits